NCT07142278View on ClinicalTrials.gov

DUVAX: A Phase 1 Alzheimer's Vaccine Study Targeting Amyloid-Beta and Tau

PHASE1Not yet recruitingINTERVENTIONAL
Enrollment

24

Participants

Timeline

Start Date

November 1, 2025

Primary Completion Date

April 1, 2027

Study Completion Date

July 31, 2027

Conditions
Alzheimer DiseaseAlzheimer Disease (AD)Preclinical Alzheimer's Disease
Interventions
BIOLOGICAL

DUVAX 200 µg

Intramuscular injection of 200 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22

BIOLOGICAL

DUVAX 400 µg

Intramuscular injection of 400 µg DUVAX formulated with Adjuvant, administered at Weeks 0, 4, and 22

BIOLOGICAL

Placebo (Adjuvant only)

Intramuscular injection of placebo consisting of Adjuvant formulation in phosphate-buffered saline without active antigen, administered at Weeks 0, 4, and 22

Trial Locations (1)

33014

Palm Springs Community Health Center, Miami Lakes

Sponsors

Lead Sponsor

Nuravax, Inc.
All Listed Sponsors
collaborator

National Institute on Aging (NIA)

NIH

collaborator

Institute for Molecular Medicine

OTHER

lead

Nuravax, Inc.

INDUSTRY